AVITA Medical, Inc. (RCEL) is a Valencia, California-based therapeutic acute wound care company whose RECELL platform uses a patient's own skin cells to create a point-of-care spray-on skin suspension for thermal burns, trauma wounds, and full-thickness skin defects. The company also markets the Cohealyx dermal matrix and the PermeaDerm biosynthetic wound matrix. On Wednesday, the stock traded at $17.10, up 8.43% or $1.33 from the previous session's close of $15.77. The move was clearly to the upside, placing shares about 7% below their 52-week high. No verified company-specific catalyst explained the advance.
No verified news or fundamental catalyst found in company releases, regulatory filings, or wire coverage coincided with Wednesday's advance. That points to a technical and positioning-driven explanation. The stock had fallen in four straight sessions from $17.65 on Nov. 10 to $15.22 on Nov. 16 — a pullback of roughly 14% from a 52-week high of $18.43 — even as the underlying business news flow stayed positive. Wednesday's action is consistent with buyers stepping back in after that decline, aided by a market that has repeatedly rewarded this name on strong volume. Liquidity is a factor: with roughly 31.4 million shares outstanding and a float turn of only a few percent on a typical day, order flow of this size can move the quote disproportionately. The stock has also been volatile by nature, averaging a 3.04% absolute daily swing over the past 60 sessions, so an 8%-class move is large but not unprecedented for this issuer.
While nothing new broke on Wednesday, the sentiment floor was built in the preceding two weeks. Third-quarter revenue reached $26.1 million, up 53% year over year and ahead of consensus, with U.S. RECELL revenue of $22.4 million and RECELL gross margin of 88.4%. Management raised full-year revenue guidance for the second consecutive quarter to $92 million to $94 million and reiterated an expectation of cash-flow breakeven in the fourth quarter. Analysts responded: BTIG lifted its target to $21 from $15, Lake Street moved to $20 from $12, and TD Cowen raised its target to $22 from $20. Coverage sentiment now sits at a strong buy consensus. Separately, AVITA published complete Cohealyx I study results, including six-month follow-up, showing a median 11 days to graft readiness, 88% of assessed wounds healed at eight weeks, improving scar scores, and no Cohealyx-related adverse events. That combination of accelerating revenue, improving margins, and clinical validation is what has kept the stock near its highs despite sharp two-way swings.
Volume was elevated relative to normal. Roughly 219,000 shares had changed hands by early afternoon, a pace comfortably ahead of what would be needed to match the three-month average of about 433,000 shares, and turnover was running at a volume ratio near 1.7 times normal. The session's range was wide, spanning a low of $15.71 to a high of $17.64, an amplitude of more than 12%. That intraday spread is characteristic of thin, momentum-sensitive small-cap medtech trading rather than of a broad sector re-rating. The move was not accompanied by an identifiable industry-wide catalyst, and the advance stands in contrast to the stock's own recent four-day slide, making this a stock-specific recovery rather than part of a wider risk-on rotation. Technically, shares reclaimed the $16.50 area that had capped the early-week bounce and pushed back toward the November highs, while remaining far above both the 50-day and 200-day moving averages.
The score runs on a 0-to-100 scale where 0 means no meaningful news and a price move that is normal for the stock, and 100 means transformative news paired with an extreme, rare move. Here the score is 14 out of 100. No verified news was published on the day of the move; the fundamental backdrop — an earnings beat, a guidance raise, and positive clinical data — is real and material but predates Wednesday, so the news component is minimal. The price component is also modest: the 8.43% gain was about 2.8 times the stock's typical daily move of 3.04%, and a move of that size or larger occurred only once in the last 60 sessions. No fresh catalyst plus a big-but-not-rare move leaves the score low.
The next hard data point is the fourth-quarter and full-year 2026 report, expected in February, when investors will test whether the company delivered on its $92 million to $94 million revenue range and reached its stated cash-flow breakeven target. Management has flagged a cash use in the first quarter of 2027 from one-time items, including a $3 million partner payment, before turning consistently cash generative. Commercial adoption metrics — RECELL unit volumes, Cohealyx hospital value-analysis approvals, and PermeaDerm reorder rates — matter more than the headline top line. The finalized national Medicare physician payment framework and simplified CPT coding for RECELL procedures take effect Jan. 1, 2027, a potential reimbursement tailwind that also carries execution risk. Analysts currently expect continued growth but no GAAP profitability this year, and the balance sheet, though strengthened by a $10 million credit draw, remains a watch item.
Tickeron's Trending AI Robots page is a curated window into the platform's automated trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but this section surfaces only the strongest performers under current market conditions. Because bots differ in strategy, timeframe, performance metrics, and the symbols they trade, the featured list changes as market conditions shift. Reviewing the current leaders can help traders compare approaches before deciding how to put automated strategies to work.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
RCEL's Aroon Indicator triggered a bullish signal on November 18, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 183 similar instances where the Aroon Indicator showed a similar pattern. In 165 of the 183 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 67 cases where RCEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on RCEL as a result. In 80 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +10.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCEL advanced for three days, in 221 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The 10-day RSI Indicator for RCEL moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Moving Average Convergence Divergence Histogram (MACD) for RCEL turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 42 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
RCEL broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RCEL's P/B Ratio (-18.431) is slightly lower than the industry average of (4.142). P/E Ratio (-11.521) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. RCEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development and distribution of regenerative and respiratory medicine and treatments
Industry MedicalNursingServices